Comparing Lucira Health (NASDAQ:LHDXQ) and Myriad Genetics (NASDAQ:MYGN)

Defense World ·  May 4, 2023 13:33

Myriad Genetics (NASDAQ:MYGN – Get Rating) and Lucira Health (NASDAQ:LHDXQ – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Valuation & Earnings

This table compares Myriad Genetics and Lucira Health's gross revenue, earnings per share (EPS) and valuation.

Get Myriad Genetics alerts:
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Myriad Genetics $678.40 million 2.63 -$112.00 million ($1.39) -15.75
Lucira Health $93.06 million 0.02 -$64.83 million ($3.58) -0.01

Lucira Health has lower revenue, but higher earnings than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Lucira Health, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Myriad Genetics and Lucira Health, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Myriad Genetics 0 2 1 0 2.33
Lucira Health 0 0 0 0 N/A

Myriad Genetics currently has a consensus target price of $27.00, suggesting a potential upside of 23.34%. Given Myriad Genetics' higher possible upside, research analysts clearly believe Myriad Genetics is more favorable than Lucira Health.

Insider & Institutional Ownership

99.1% of Myriad Genetics shares are held by institutional investors. Comparatively, 57.0% of Lucira Health shares are held by institutional investors. 1.8% of Myriad Genetics shares are held by insiders. Comparatively, 30.4% of Lucira Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.


This table compares Myriad Genetics and Lucira Health's net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Myriad Genetics -16.51% -5.83% -4.42%
Lucira Health -67.54% -13.55% -8.47%

Volatility and Risk

Myriad Genetics has a beta of 1.84, indicating that its share price is 84% more volatile than the S&P 500. Comparatively, Lucira Health has a beta of 3.36, indicating that its share price is 236% more volatile than the S&P 500.


Myriad Genetics beats Lucira Health on 9 of the 13 factors compared between the two stocks.

About Myriad Genetics

(Get Rating)

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

About Lucira Health

(Get Rating)

Lucira Health Inc. is a medical technology company. It is focused on the development and commercialization of transformative and infectious disease test kits. Lucira Health Inc. is based in Emeryville, California.

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with's FREE daily email newsletter.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment